Rapid diagnosis of cryptococcal meningitis by use of lateral flow assay on cerebrospinal fluid samples: Influence of the high-dose "hook" effect

Journal of Clinical Microbiology

Volumn 52, Issue 12, 2014, Pages 4172-4175

  Lourens, Adré ^a   Jarvis, Joseph N ^b,c,d   Meintjes, Graeme ^e   Samuel, Catherine M ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c BOTSWANA UPENN PARTNERSHIP   (Botswana)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

FUNGUS ANTIGEN; BACTERIAL ANTIGEN;

ADULT; ANTIGEN DETECTION; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CRYPTOCOCCAL MENINGITIS; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FUNGUS CULTURE; GRAM STAINING; HUMAN; INTERMETHOD COMPARISON; LATERAL FLOW ASSAY; LATEX AGGLUTINATION TEST; MAJOR CLINICAL STUDY; MICROSCOPY; RELIABILITY; SENSITIVITY AND SPECIFICITY; ADOLESCENT; AFRICA; CEREBROSPINAL FLUID; CHEMISTRY; CHILD; COMPLICATION; EVALUATION STUDY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOAFFINITY CHROMATOGRAPHY; INFANT; LABORATORY DIAGNOSIS; MENINGITIS, CRYPTOCOCCAL; MIDDLE AGED; PRESCHOOL CHILD; PROCEDURES; PROSPECTIVE STUDY; TIME;

ADOLESCENT; ADULT; AFRICA; ANTIGENS, BACTERIAL; CEREBROSPINAL FLUID; CHILD; CHILD, PRESCHOOL; FALSE NEGATIVE REACTIONS; HIV INFECTIONS; HUMANS; IMMUNOCHROMATOGRAPHY; INFANT; MENINGITIS, CRYPTOCOCCAL; MICROSCOPY; MIDDLE AGED; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 84910127961     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01683-14     Document Type: Article

References (24)

1. Vijayan T, Chiller T, Klausner JD. 2013. Sensitivity and specificity of a new cryptococcal antigen lateral flow assay in serum and cerebrospinal fluid. MLO Med. Lab Obs. 45:16, 18, 20.
2. Springer DJ, Chaturvedi V. 2010. Projecting global occurrence of Cryptococcus gattii. Emerg. Infect. Dis. 16:14-20. http://dx.doi.org/10.3201/eid1601.090369.
3. French N, Gray K, Watera C, Nakiyingi J, Lugada E, Moore M, Lalloo D, Whitworth JAG, Gilks CF. 2002. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS 16:1031-1038. http://dx.doi.org/10.1097/00002030-200205030-00009.
4. Jarvis JN, Meintjes G, Williams A, Brown Y, Crede T, Harrison TS. 2010. Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases. BMC Infect. Dis. 10:67. http://dx.doi.org/10.1186/1471-2334-10-67.
5. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. 2009. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23:525-530. http://dx.doi.org/10.1097/QAD.0b013e328322ffac.
6. Jarvis J, Meintjes G. 2011. Cryptococcal meningitis - a neglected killer: editorial. S. Afr. Med. J. 101:244-245.
7. Lessells RJ, Mutevedzi PC, Heller T, Newell M-L. 2011. Poor long-term outcomes for cryptococcal meningitis in rural South Africa. S. Afr. Med. J. 101:251-252.
8. Bicanic T, Meintjes G, Wood R, Hayes M, Rebe K, Bekker LG, Harrison T. 2007. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin. Infect. Dis. 45:76-80. http://dx.doi.org/10.1086/518607.
9. Bicanic T, Wood R, Meintjes G, Rebe K, Brouwer A, Loyse A, Bekker LG, Jaffar S, Harrison T. 2008. High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin. Infect. Dis. 47:123-130. http://dx.doi.org/10.1086/588792.
10. Harrison TS. 2009. The burden of HIV-associated cryptococcal disease. AIDS 23:531-532. http://dx.doi.org/10.1097/QAD.0b013e328322ffc3.
11. Anekthananon T, Manosuthi W, Chetchotisakd P, Kiertiburanakul S, Supparatpinyo K, Ratanasuwan W, Pappas PG, Filler SG, Kopetskie HA, Nolen TL, Kendrick AS, Larsen RA, BAMSG 3-01 Study Team. 2011. Predictors of poor clinical outcome of cryptococcal meningitis in HIV-infected patients. Int. J. STD AIDS 22:665-670. http://dx.doi.org/10.1258/ijsa.2011.010538.
12. Jarvis JN, Bicanic T, Harrison TS. 2007. Treatment of HIV-associated cryptococcal meningitis in South Africa: the case for amphotericin B over conventional dose fluconazole for initial therapy. S. Afr. J. HIV Med. 8:36-39.
13. Jarvis JN, Bicanic T, Loyse A, Namarika D, Jackson A, Nussbaum JC, Longley N, Muzoora C, Phulusa J, Taseera K, Kanyembe C, Wilson D, Hosseinipour MC, Brouwer AE, Limmathurotsakul D, White N, van der Horst C, Wood R, Meintjes G, Bradley J, Jaffar S, Harrison T. 2014. Determinants of mortality in a combined cohort of 501 patients with HIVassociated cryptococcal meningitis: implications for improving outcomes. Clin. Infect. Dis. 58:736-745. http://dx.doi.org/10.1093/cid/cit794.
14. Mora DJ, da Cunha Colombo ER, Ferreira-Paim K, Andrade-Silva LE, Nascentes GA, Silva-Vergara ML. 2012. Clinical, epidemiological and outcome features of patients with cryptococcosis in Uberaba, Minas Gerais, Brazil. Mycopathologia 173:321-327. http://dx.doi.org/10.1007/s11046-011-9504-9.
15. Barenfanger J, Lawhorn J, Drake C. 2004. Nonvalue of culturing cerebrospinal fluid for fungi. J. Clin. Microbiol. 42:236-238. http://dx.doi.org/10.1128/JCM.42.1.236-238.2004.
16. Jarvis JN, Percival A, Bauman S, Pelfrey J, Meintjes G, Williams GN, Longley N, Harrison TS, Kozel TR. 2011. Evaluation of a novel pointof- care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis. Clin. Infect. Dis. 53: 1019-1023. http://dx.doi.org/10.1093/cid/cir613.
17. Lindsley MD, Mekha N, Baggett HC, Autthateinchai R, Sawatwong P, Harris JR, Park BJ, Chiller T, Balajee SA, Poonwan N. 2011. Evaluation of a newly developed lateral flow immunoassay for the diagnosis of cryptococcosis. Clin. Infect. Dis. 53:321-325. http://dx.doi.org/10.1093/cid/cir379.
18. IMMY. 2012. CrAg LFA package insert. IMMY, Norman, OK. http://www.immy.com/products/cryptococcal-antigen-lateral-flow-assay-lfa/.
19. Graf B, Adam T, Zill E, Göbel UB. 2000. Evaluation of the VITEK 2 system for rapid identification of yeast and yeast like organisms. J. Clin. Microbiol. 38:1782-1785.
20. Remel, Inc. 2009. CLAT package insert. Product no. R30851501. Remel, Inc., Lenexa, KS.
21. Qin Z, Chan WCW, Boulware DR, Akkin T, Butler EK, Bischof JC. 2012. Significantly improved analytical sensitivity of lateral flow immunoassays by using thermal contrast. Angew. Chem. Int. Ed. Engl. 51:4358-4361. http://dx.doi.org/10.1002/anie.201200997.
22. Gates-Hollingsworth M.A, Kozel TR. 2013. Serotype sensitivity of a lateral flow immunoassay for cryptococcal antigen. Clin. Vaccine Immunol. 20:634-635. http://dx.doi.org/10.1128/CVI.00732-12.
23. Hansen J, Slechta ES, Gates-Hollingsworth MA, Neary B, Barker AP, Bauman S, Kozel TR, Hanson KE. 2013. Large-scale evaluation of the immuno-mycologics lateral flow and enzyme-linked immunoassay for detection of cryptococcal antigen in serum and cerebrospinal fluid. Clin. Vaccine Immunol. 20:52-55. http://dx.doi.org/10.1128/CVI.00536-12.
24. Boulware DR, Rolfes MA, Rajasingham R, Von Hohenberg M, Qin Z, Taseera K, Schutz C, Kwizera R, Butler EK, Meintjes G, Muzoora C, Bischof JC, Meya DB. 2014. Multisite validation of cryptococcal antigen lateral flow assay and quantification by laser thermal contrast. Emerg. Infect. Dis. 20:45-53. http://dx.doi.org/10.3201/eid2001.130906.